FDA says anemia drug peginesatide is comparable to other treatments

12/5/2011 | Reuters

FDA drug reviewers said Affymax's peginesatide, a treatment for anemia in dialysis patients with chronic kidney disease, performs comparably with Amgen's Epogen and Aranesp in maintaining an ideal hemoglobin level. However, reviewers voiced concern about peginesatide's safety profile. An FDA panel is set to review the drug Wednesday, and the agency's final decision is anticipated by March 27.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Manager/Senior Manager, Health Services Analytics
Avalere Health
Washington, DC
Manager/Senior Manager, Health Economist
Avalere Health
Washington, DC
Director, Health Services Analytics
Avalere Health
Washington, DC
Director/Vice President. Health Actuary
Avalere Health
Washington, DC
Director of Governmental Programs
Bluegrass Family Health
Lexington, KY